Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.

@article{Gold2011OralTF,
  title={Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.},
  author={Ralf Gold},
  journal={CNS drugs},
  year={2011},
  volume={25 1},
  pages={37-52}
}
Several disease-modifying therapies are approved for the management of multiple sclerosis (MS). While reasonably effective, these therapies require long-term parenteral self-injection, which is inconvenient for some patients and can be associated with injection-related adverse effects. Consequently, there is a need in MS for an oral therapy option… CONTINUE READING